In the clinical settings of chronic supra-physiological growth hormone and IGF-1 levels in patients with acromegaly, the risk to development of malignancies is still controversial (Loeper & Ezzat 2008, Boguszewski & Ayuk 2016, Boguszewski & Boguszewski 2019). The gene discussed is IGF1; the disease is acromegaly.